Efficacy of an anti-fertility vaccine based on mammalian gonadotrophin releasing hormone (GnRH-I)—a histological comparison in male animals

Ferro, Valerie A.; Khan, Md. Abu Hadi Noor Ali; McAdam, Doris; Colston, Angela; Aughey, E.; Mullen, Alexander B.; Waterston, Mary; Harvey, Michael J.

doi:10.1016/j.vetimm.2004.03.011

Cited by 50 publications

(40 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As it has been shown in many investigations published during the last years [3][4][5][6][7][8][9][10]17,20,[29][30][31][32][33][34] vaccination against GnRF was able to induce an increase in anti-GnRF antibody titer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination against gonadotropin-releasing factor (GnRF) with Bopriva significantly decreases testicular development, serum testosterone levels and physical activity in pubertal bulls

Janett

Gerig

Tschuor³

et al. 2012

Theriogenology

View full text Add to dashboard Cite

The aim of this study was to evaluate the effects of vaccination against gonadotropin-releasing factor (GnRF) on testicular development, testosterone secretion, and physical activity in pubertal bulls. The experiment was performed using 44 bulls aged between 6 and 7 mo. Twenty-three animals were vaccinated twice 4 wk apart with 1 mL of Bopriva (Pfizer, Animal Health, Parkville, Australia) and 21 bulls served as matched controls. Serum GnRF antibody titer and testosterone concentration as well as body weight and scrotal circumference were determined in all bulls for 24 wk from the first vaccination. In addition, physical activity was analyzed in 11 vaccinated and in 10 control animals using the ALPRO DeLaval activity meter system (DeLaval AG, Sursee, Switzerland). The results show that vaccination significantly (P < 0.05) influenced all parameters evaluated except body weight. Antibody titers to GnRF began to rise 2 wk after the first vaccination and reached peak values 2 wk after the second injection. Significant group differences in anti-GnRF titer were present for 22 wk following the first vaccination. Testosterone concentrations were significantly lower between weeks 6 to 24 after first vaccination in bulls with Bopriva compared with control animals. In vaccinated bulls testicular development was impaired after the second injection and scrotal circumference was significantly smaller between weeks 8 to 24 after first vaccination. Physical activity of vaccinated bulls was reduced after the booster injection with significant group differences for a continuous period of 106 days. In conclusion, vaccination against GnRF with Bopriva in pubertal bulls decreased testosterone levels in peripheral blood, testicular development, and physical activity but did not affect weight gain. AbstractThe aim of this study was to evaluate the effects of vaccination against gonadotropinreleasing factor (GnRF) on testicular development, testosterone secretion and physical activity in pubertal bulls. The experiment was performed using 44 bulls aged between 6 and 7 months. Twenty-three animals were vaccinated twice 4 weeks apart with 1 mL of Bopriva ® (Pfizer Animal Health, Australia) and 21 bulls served as matched controls. Serum GnRF antibody titer and testosterone concentration as well as body weight and scrotal circumference were determined in all bulls for 24 weeks from the first vaccination. In addition, physical activity was analyzed in 11 vaccinated and in 10 control animals using the ALPRO  DeLaval activity meter system (DeLaval AG, Sursee, Switzerland). The results show that vaccination significantly (P < 0.05) influenced all parameters evaluated except body weight. Antibody 2 titers to GnRF began to rise 2 weeks after the first vaccination and reached peak values 2 weeks after the second injection. Significant group differences in anti-GnRF titer were present for 22 weeks following the first vaccination. Testosterone concentrations were significantly lower between weeks 6 to 24 after first vaccination in bulls w...

show abstract

Section: Discussionmentioning

confidence: 99%

“…The suppression of reproductive function using an anti-GnRF vaccine has been demonstrated in numerous studies in cattle [3][4][5][6][7][8][9][10][11][12][13], sheep [10,[14][15][16][17][18][19][20][21], pig [22][23][24][25][26][27][28], horse [29][30][31][32][33][34] and in wild animals [35][36][37][38][39].…”

Section: Introductionmentioning

confidence: 99%

Vaccination against gonadotropin-releasing factor (GnRF) with Bopriva significantly decreases testicular development, serum testosterone levels and physical activity in pubertal bulls

Janett

Gerig

Tschuor³

et al. 2012

Theriogenology

View full text Add to dashboard Cite

show abstract

“…The vaccination of male dogs with N-terminal modified GnRH conjugated to tetanus toxoid did not display any significant arrest in testicular spermatogenesis with only a 5% decrease in activity compared to untreated animals (Ferro et al, 2004).…”

Section: Gnrh Immunizationmentioning

confidence: 76%

Chemical Control of Fertility in Male Dogs: A Review

Soni¹,

Pandey²

2018

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

“…Development of a GnRH vaccine is problematic because GnRH is a well preserved peptide among species, it has only ten amino acids and it is not naturally immunogenic. Several studies carried out with GnRH molecules conjugated to various antigens to mobilize T-helper cells have shown promising results in the dog, but its effects on the bitch or in the queen have not been studied in detail (LADD et al, 1994;FERRO et al, 2004;JUNG et al, 2005;KUTZLER;WOOD, 2006).…”

Section: Conservative Treatment/management Of Orsmentioning

confidence: 99%

Ovarian remnant syndrome in small animals

et al. 2012

View full text Add to dashboard Cite

The ovarian remnant syndrome (ORS) is an iatrogenic disorder in bitches and queens, which is characterized by recurrence of estrus following surgical spay, due to the presence of a piece of ovarian tissue within the abdominal cavity. In most cases, the remnant ovary is found in the right ovarian pedicle, due to its topographic position, deeper and more cranial than the left ovary. The main clinical signs of ORS in small animals are the heat behavior and the presence of vaginal swelling/secretion, especially in canines. The diagnosis should be performed by means of vaginal cytology when attraction of males is detected, serum estrogen and progesterone levels and/or by challenging test with GnRH or hCG administration. However, vaginal citology is the most suitable and less expensive diagnostic tool. Nowadays the treatment of choice is a new laparotomy or laparoscopy, followed by removal of the remnant ovarian tissue. The surgical treatment has more chances of success if it is performed in the diestrus (i.e., between 15 and 60 days after the detection of attraction of males). Furthermore, a careful and accurate surgical procedure aided by advanced visualization techniques during ovariohysterectomy or ovariectomy is the best way to prevent ORS in companion animals. Key words: Partial ovarian spay, recurrent estrus, bitches, queens ResumoA síndrome do ovário remanescente (SOR) é um distúrbio iatrogênico em cadelas e gatas caracterizado pelo retorno do estro após contracepção cirúrgica devido à presença de fragmento de tecido ovariano na cavidade abdominal. Frequentemente, o ovário remanescente está situado no pedículo ovariano direito, sobretudo devido a sua posição topográfica mais profunda e cranial em comparação ao ovário esquerdo. Os principais sinais clínicos de SOR em pequenos animais são cio e presença de edemaciamento/secreção vulvar/vaginal, especialmente em caninos. O diagnóstico deve ser realizado por meio de citologia vaginal quando detecta-se o interesse dos machos pela cópula com a fêmea acometida, dosagem sérica de estrógeno e progesterona e/ou por meio do teste provocativo com administração de GnRH ou hCG. Contudo, citologia vaginal constitui a opção de melhor custo-benefício para o diagnóstico. Atualmente, o tratamento de escolha é cirúrgico por meio de laparotomia exploratória ou laparoscopia, seguido pela remoção do ovário remanescente. O tratamento cirúrgico tem maiores taxas de sucesso quando realizado com o animal em diestro (i.e., entre 15 e 60 dias após detectada a atração dos machos). Ademais, a

show abstract

Efficacy of an anti-fertility vaccine based on mammalian gonadotrophin releasing hormone (GnRH-I)—a histological comparison in male animals

Cited by 50 publications

References 32 publications

Vaccination against gonadotropin-releasing factor (GnRF) with Bopriva significantly decreases testicular development, serum testosterone levels and physical activity in pubertal bulls

Vaccination against gonadotropin-releasing factor (GnRF) with Bopriva significantly decreases testicular development, serum testosterone levels and physical activity in pubertal bulls

Chemical Control of Fertility in Male Dogs: A Review

Ovarian remnant syndrome in small animals

Contact Info

Product

Resources

About